The use of trastuzumab in New Zealand women with breast cancer

The use of trastuzumab in New Zealand women with breast cancer 1INTRODUCTIONIn New Zealand, the presence of the biomarker human epidermal growth factor receptor 2 (HER2) in women with breast cancer has been commonly ascertained since 1998, and routinely since 2006. It has been found to be present in approximately 15–20% of breast cancers, presenting more commonly in breast cancers of younger women. It is known that women who have HER2 positive (+ve) breast cancer have a poorer prognosis compared to women with HER2 negative (–ve) disease.Trastuzumab (Herceptin) is a targeted therapy for patients with HER2+ve breast cancer. Randomized clinical trials have shown that trastuzumab reduced breast cancer recurrence and mortality in women with early‐stage HER2+ve breast cancer after surgery. A study combining data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B‐31 and North Central Cancer Treatment Group (NCCTG) N9831 clinical trials with a median follow‐up time of 8 years demonstrated a hazard ratio of 0.63 (95% CI: 0.54–0.73) in breast cancer‐specific mortality and a hazard ratio of 0.60 (95% CI: 0.53–0.68) in all‐cause mortality after adding 12 months trastuzumab to chemotherapy for HER2+ve stage I–III breast cancer.Trastuzumab was first licensed by the US FDA (Federal Drug Regulatory Authority) in 1998 for metastatic HER2+ve breast cancer and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asia-Pacific Journal of Clinical Oncology Wiley
Loading next page...
 
/lp/wiley/the-use-of-trastuzumab-in-new-zealand-women-with-breast-cancer-iiDPia7zt4
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 John Wiley & Sons Australia, Ltd
ISSN
1743-7555
eISSN
1743-7563
D.O.I.
10.1111/ajco.12766
Publisher site
See Article on Publisher Site

Abstract

1INTRODUCTIONIn New Zealand, the presence of the biomarker human epidermal growth factor receptor 2 (HER2) in women with breast cancer has been commonly ascertained since 1998, and routinely since 2006. It has been found to be present in approximately 15–20% of breast cancers, presenting more commonly in breast cancers of younger women. It is known that women who have HER2 positive (+ve) breast cancer have a poorer prognosis compared to women with HER2 negative (–ve) disease.Trastuzumab (Herceptin) is a targeted therapy for patients with HER2+ve breast cancer. Randomized clinical trials have shown that trastuzumab reduced breast cancer recurrence and mortality in women with early‐stage HER2+ve breast cancer after surgery. A study combining data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B‐31 and North Central Cancer Treatment Group (NCCTG) N9831 clinical trials with a median follow‐up time of 8 years demonstrated a hazard ratio of 0.63 (95% CI: 0.54–0.73) in breast cancer‐specific mortality and a hazard ratio of 0.60 (95% CI: 0.53–0.68) in all‐cause mortality after adding 12 months trastuzumab to chemotherapy for HER2+ve stage I–III breast cancer.Trastuzumab was first licensed by the US FDA (Federal Drug Regulatory Authority) in 1998 for metastatic HER2+ve breast cancer and

Journal

Asia-Pacific Journal of Clinical OncologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off